Albert Robichaud

All filings by Albert Robichaud on record concern Sage Therapeutics, Inc., in the capacity of senior executive. We count 38 filings; the first trade dates from 23 July 2014 and the latest from 3 February 2023.

In open-market terms, that means 2 purchases worth €1.5M on one side and 18 sales worth €12.5M on the other. The net balance comes to €11.0M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 8 share grants and 4 option exercises.

On 7 February 2023 came the latest disclosure, a share grant for €46k in Sage Therapeutics, Inc. The last insider purchase was made public on 10 December 2019, 2,526 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.